EPCAM and ovarian carcinoma: Even though previous studies have monitored specific populations of CTCs in patients with ovarian cancer, such as ERCC1, EpCAM, HE4 or Her2 positive CTCs to predict the tumor evolution and the therapy response [3,8,9,10], the biology of this circulating population is still quite unexplored.